CSX
57
-4
AMAT
33
-13
GD
41
-4
PVH
60
-4
STZ
52
-6
MDLZ
32
-4
KHC
9
-4
NOV
52
-5
O
17
-13
CMI
64
-3
THC
60
-5
NEE
54
7
PFE
14
-7
LUV
45
-2
DHR
32
-6
TXN
43
-5
ICE
59
-3
ISRG
71
-5
PSA
56
3
AZO
50
-5
CSX
57
-4
AMAT
33
-13
GD
41
-4
PVH
60
-4
STZ
52
-6
MDLZ
32
-4
KHC
9
-4
NOV
52
-5
O
17
-13
CMI
64
-3
THC
60
-5
NEE
54
7
PFE
14
-7
LUV
45
-2
DHR
32
-6
TXN
43
-5
ICE
59
-3
ISRG
71
-5
PSA
56
3
AZO
50
-5
Financhill
Back

Structure Therapeutics Quote, Financials, Valuation and Earnings

Trump's "Document 20" Revealed: Smart Americans Could Get Rich During His 2nd Term

See if stocks could soar as much as 1,000% if history repeats itself.
Sell
18

GPCR
Structure Therapeutics

Last Price:
34.18
Seasonality Move:
-11.15%

7 Day Trial

ALL ACCESS PASS

$ 7

Buy these stocks BEFORE President Trump returns to the Oval Office

See details on which stocks are poised to surge.

Structure Therapeutics Price Quote

$34.18
+0.01 (+-9.31%)
(Updated: November 16, 2024 at 5:20 AM ET)

Structure Therapeutics Key Stats

Sell
18
Structure Therapeutics (GPCR) is a Sell
Day range:
$33.92 - $37.76
52-week range:
$26.61 - $66.38
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
2.12%
Volume:
1.1M
Avg. volume:
697.9K
1-year change:
-29.28%
Market cap:
$2B
Revenue:
$0
EPS:
$-2.22

How Much Does Structure Therapeutics Make?

Data Unavailable

Is Structure Therapeutics Growing As A Company?

Data Unavailable

Structure Therapeutics Stock Price Performance

What Is Structure Therapeutics 52-Week High & Low?

Structure Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Structure Therapeutics?

Is Structure Therapeutics Cash Flow Positive?

  • What Is GPCR Cash Flow From Operations?
    Cash flow from operations (TTM) is -$102.8M
  • What Is Structure Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $797.5M
  • What Is Structure Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$353.7M

Structure Therapeutics Return On Invested Capital

Data Unavailable

Structure Therapeutics Earnings Date & Stock Price

Structure Therapeutics Competitors

Structure Therapeutics Dividend Yield

Structure Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -7.14%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 6
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 85.82
Upside from Last Price: 151.15%

Major Shareholders

  • How many GPCR shares are owned by institutional investors?
    130M GPCR shares are owned by institutional investors
  • How many GPCR shares are owned by insiders?
    2.2M GPCR shares are owned by insiders